Genmab AS Company Top Insiders
GNMSF Stock | USD 224.97 1.96 0.86% |
Genmab AS employs about 1.6 K people. The company is managed by 10 executives with a total tenure of roughly 21 years, averaging almost 2.0 years of service per executive, having 156.0 employees per reported executive. Examination of Genmab AS's management performance can provide insight into the company performance.
Jan Winkel CEO President and CEO |
Anthony Pagano President Senior Vice President Global Finance |
Genmab |
Genmab AS Management Team Effectiveness
The company has return on total asset (ROA) of 0.1029 % which means that it generated a profit of $0.1029 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2359 %, meaning that it generated $0.2359 on every $100 dollars invested by stockholders. Genmab AS's management efficiency ratios could be used to measure how well Genmab AS manages its routine affairs as well as how well it operates its assets and liabilities.Genmab AS Workforce Comparison
Genmab AS is one of the top stocks in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 7,417. Genmab AS totals roughly 1,560 in number of employees claiming about 21% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of 0.47 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.38 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.38. Genmab AS Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Genmab AS Price Series Summation is a cross summation of Genmab AS price series and its benchmark/peer.
Genmab AS Notable Stakeholders
A Genmab AS stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Genmab AS often face trade-offs trying to please all of them. Genmab AS's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Genmab AS's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Jan Winkel | President and CEO | Profile | |
Anthony Pagano | Senior Vice President Global Finance | Profile | |
Tahamtan Ahmadi | Senior Vice President Oncology and Translational Medicine | Profile | |
Andrew Carlsen | Senior Director, Investor Relations | Profile | |
Anthony Mancini | Ex COO | Profile | |
Birgitte MSc | Ex Officer | Profile | |
Judith MD | Exec Officer | Profile | |
Peter Ros | Sr Accounting | Profile | |
Mijke Zachariasse | Director Director | Profile | |
Rima Nassar | Head VP | Profile |
About Genmab AS Management Performance
The success or failure of an entity such as Genmab AS often depends on how effective the management is. Genmab AS management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Genmab management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Genmab management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on OTC Exchange in the United States.
Genmab AS Workforce Analysis
Traditionally, organizations such as Genmab AS use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Genmab AS within its industry.Genmab AS Manpower Efficiency
Return on Genmab AS Manpower
Revenue Per Employee | 5.4M | |
Revenue Per Executive | 848.2M | |
Net Income Per Employee | 1.9M | |
Net Income Per Executive | 300.8M | |
Working Capital Per Employee | 2.4M | |
Working Capital Per Executive | 372.3M |
Complementary Tools for Genmab Pink Sheet analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |